Genaera Liquidating Trust To Sell Remaining Proprietary Assets

Genaera liquidating trust

The trustee will

Neither the Trustee nor the Trust has received any notice of breach or default under the License Agreement or any of the Ludwig Agreements. AstraZeneca, through its subsidiary, MedImmune, Inc. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. You are encouraged to read these reports.

Ligand is committed to constantly exploring and executing business arrangements that deliver long-term value to our shareholders. In addition, Ligand may not be able to successfully implement its strategic growth plan or continue the development of its proprietary programs. Seller has not incurred any liability to any broker, finder or agent with respect to the payment of any commission regarding the consummation of the transactions contemplated hereby.

This section may

The Trust agrees to cooperate with and to assist Purchaser in the collection and allocations of such amounts. No assurances can be given as to the amount or timing of any distributions by the Trust. Stockholders of the Company on the record date are not required to take any action to receive Units.

Actual events or results

Purchase and Sale Agreement

The trustee will maintain a record of the name and address of each beneficiary and such beneficiary's aggregate Units in the Trust. This section may also have questions seeking help. Actual events or results may differ from Ligand's expectations.

Forward-Looking Statements This news release contains certain forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of that are subject to risks and uncertainties, known and unknown.

Representations and Warranties of Seller. The Purchased Assets constitute substantially all of the assets of the Trust. Genaera does not intend and it is not obligated to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto. The Trust will be organized for the sole purpose of winding up the Company's affairs and the liquidation of its assets. As such, the Trust will be a complete pass-through entity for federal income tax purposes and, accordingly, will not itself be subject to federal income tax.